ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 277 filers reported holding ROYALTY PHARMA PLC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,508,336 | -3.4% | 2,597,949 | +9.4% | 0.01% | 0.0% |
| Q2 2023 | $72,967,169 | -18.3% | 2,373,688 | -4.2% | 0.01% | -22.2% |
| Q1 2023 | $89,272,540 | -7.0% | 2,477,728 | +2.0% | 0.02% | -10.0% |
| Q4 2022 | $96,011,982 | +1.7% | 2,429,453 | +3.4% | 0.02% | -9.1% |
| Q3 2022 | $94,450,000 | -5.7% | 2,350,684 | -1.4% | 0.02% | +4.8% |
| Q2 2022 | $100,183,000 | +6.8% | 2,383,034 | -1.1% | 0.02% | +23.5% |
| Q1 2022 | $93,842,000 | +4.1% | 2,408,684 | +6.5% | 0.02% | +13.3% |
| Q4 2021 | $90,126,000 | +49.4% | 2,261,622 | +35.5% | 0.02% | +36.4% |
| Q3 2021 | $60,306,000 | +20.7% | 1,668,674 | +36.9% | 0.01% | +22.2% |
| Q2 2021 | $49,946,000 | -12.3% | 1,218,491 | -6.7% | 0.01% | -18.2% |
| Q1 2021 | $56,952,000 | +52.3% | 1,305,633 | +74.7% | 0.01% | +57.1% |
| Q4 2020 | $37,405,000 | +61.6% | 747,359 | +35.9% | 0.01% | +40.0% |
| Q3 2020 | $23,141,000 | +200.0% | 550,041 | +246.2% | 0.01% | +150.0% |
| Q2 2020 | $7,713,000 | – | 158,876 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |